Syndax Pharmaceuticals (SNDX) Financials

$10.57 -0.05 (-0.47%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$10.98 +0.41 (+3.87%)

As of 05/30/2025 07:50 PM Eastern

Annual Income Statements for Syndax Pharmaceuticals

This table shows Syndax Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-319	-209	-149	25	-77	-56	-74	-61	-47	-104	-26
Consolidated Net Income / (Loss)	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Net Income / (Loss) Continuing Operations	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Total Pre-Tax Income	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Total Operating Income	-340	-230	-152	26	-71	-58	-76	-62	-44	-21	-21
Total Gross Profit	24	0.00	0.00	140	1.52	1.52	1.52	2.11	1.22	0.63	0.00
Total Revenue	24	0.00	0.00	140	1.52	1.52	1.52	2.11	1.22	0.63	0.00
Operating Revenue	24	0.00	0.00	140	1.52	1.52	1.52	2.11	1.22	0.63	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	363	230	152	113	73	59	77	64	45	21	21
Selling, General & Admin Expense	121	67	33	25	23	16	17	16	13	12	11
Research & Development Expense	242	163	118	88	50	43	60	48	32	9.55	10
Total Other Income / (Expense), net	21	21	2.42	-1.29	-1.74	1.49	1.92	1.15	-0.71	-3.61	1.50
Interest Expense	4.93	0.21	3.14	1.90	2.36	0.00	0.00	-	-	-	-
Interest & Investment Income	26	21	5.87	0.40	0.84	1.57	1.94	1.42	0.96	-1.41	-0.29
Other Gains / (Losses), net	-0.25	-	-	-	-	-	-	-	-	-	-
Basic Earnings per Share	($3.72)	($2.98)	($2.46)	$0.48	($1.87)	($1.84)	($2.92)	($2.90)	($3.22)	($1,519.27)	($453.02)
Weighted Average Basic Shares Outstanding	85.62M	70.37M	60.76M	52.06M	41.31M	30.49M	25.37M	21.00M	14.62M	68.35K	58.18K
Diluted Earnings per Share	($3.72)	($2.98)	($2.46)	$0.46	($1.87)	($1.84)	($2.92)	($2.90)	($3.22)	($1,519.27)	($453.02)
Weighted Average Diluted Shares Outstanding	85.62M	70.37M	60.76M	53.62M	41.31M	30.49M	25.37M	21.00M	14.62M	68.35K	58.18K
Weighted Average Basic & Diluted Shares Outstanding	86.02M	84.97M	68.44K	55.01M	41.31M	30.49M	25.37M	21.00M	14.62M	68.35K	58.18K

This table shows Syndax Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Consolidated Net Income / (Loss)	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Net Income / (Loss) Continuing Operations	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Total Pre-Tax Income	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Total Operating Income	-84	-96	-90	-74	-80	-78	-56	-50	-46	-42	-35
Total Gross Profit	19	7.68	13	3.50	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	20	7.68	13	3.50	0.00	-	0.00	0.00	0.00	-	0.00
Operating Revenue	20	7.68	13	3.50	0.00	-	0.00	-	0.00	-	0.00
Total Cost of Revenue	0.89	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Operating Cost of Revenue	0.89	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	103	103	102	78	80	78	56	50	46	42	35
Selling, General & Admin Expense	41	38	31	29	23	23	17	15	12	10	8.24
Research & Development Expense	62	66	71	49	56	55	39	35	34	32	27
Other Special Charges / (Income)	0.25	-	-	-	-	-	-	-	-	-	-
Total Other Income / (Expense), net	-1.09	2.44	5.45	6.15	7.11	5.43	5.21	5.06	4.89	2.96	-0.26
Interest Expense	8.05	4.81	0.02	0.05	0.06	0.06	0.07	0.04	0.04	0.04	1.75
Interest & Investment Income	7.18	7.11	5.44	6.28	7.26	5.55	5.35	5.19	5.08	2.99	1.78
Other Income / (Expense), net	-0.22	-	0.03	-0.09	-0.09	-0.06	-0.07	-0.09	-0.15	-	-0.30
Basic Earnings per Share	($0.98)	($1.09)	($0.98)	($0.80)	($0.85)	($1.02)	($0.73)	($0.64)	($0.59)	($0.63)	($0.58)
Weighted Average Basic Shares Outstanding	86.17M	85.62M	85.43M	85.27M	85.21M	70.37M	69.86M	69.64M	69.44M	60.76M	60.67M
Diluted Earnings per Share	($0.98)	($1.09)	($0.98)	($0.80)	($0.85)	($1.02)	($0.73)	($0.64)	($0.59)	($0.63)	($0.58)
Weighted Average Diluted Shares Outstanding	86.17M	85.62M	85.43M	85.27M	85.21M	70.37M	69.86M	69.64M	69.44M	60.76M	60.67M
Weighted Average Basic & Diluted Shares Outstanding	86.05M	86.02M	-	85.10M	84.99M	84.97M	69.64M	69.48M	68.82M	68.44K	60.22M

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	-141	221	-148	107	91	-9.26	-1.40	11	0.76	13	-0.10
Net Cash From Operating Activities	-275	-161	-134	29	-71	-51	-69	-47	-35	-2.43	-14
Net Cash From Continuing Operating Activities	-275	-161	-135	29	-72	-51	-69	-47	-35	-2.43	-14
Net Income / (Loss) Continuing Operations	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Consolidated Net Income / (Loss)	-319	-209	-149	25	-73	-56	-74	-61	-44	-24	-20
Depreciation Expense	0.01	-	-	-	-	0.09	0.08	0.08	0.09	0.02	0.02
Amortization Expense	-13	-15	-3.38	0.64	-	-0.78	-0.56	-0.22	-0.13	1.07	0.09
Non-Cash Adjustments To Reconcile Net Income	56	42	13	13	9.06	6.36	6.21	5.44	6.44	6.05	4.78
Changes in Operating Assets and Liabilities, net	1.27	21	5.00	-9.60	-7.93	-0.24	-0.30	8.33	2.92	15	0.55
Net Cash From Investing Activities	-220	118	-186	-41	-143	13	51	-17	-18	-62	1.89
Net Cash From Continuing Investing Activities	-220	118	-186	-41	-143	13	51	-17	-18	-62	1.89
Purchase of Investments	-557	-355	-495	-295	-279	-104	-79	-152	-158	-102	-3.39
Sale of Property, Plant & Equipment	0.00	0.00	0.23	0.00	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	337	472	309	254	136	117	130	135	140	41	5.29
Net Cash From Financing Activities	353	264	172	118	304	29	16	76	54	77	12
Net Cash From Continuing Financing Activities	353	264	172	118	304	29	16	76	54	77	12
Issuance of Common Equity	1.72	259	182	112	278	28	16	0.10	52	-	0.00
Other Financing Activities, net	352	5.13	-9.54	6.34	6.63	0.18	0.03	76	2.06	0.19	0.01
Cash Interest Paid	0.00	0.00	2.06	-	-	-	-	-	-	-	-

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-0.09	21	28	-9.22	-181	201	-2.73	40	-17	2.98	-49
Net Cash From Operating Activities	-95	-57	-62	-72	-84	-41	-45	-35	-39	-23	-29
Net Cash From Continuing Operating Activities	-95	-59	-61	-71	-84	-42	-45	-35	-39	-24	-29
Net Income / (Loss) Continuing Operations	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Consolidated Net Income / (Loss)	-85	-94	-84	-68	-72	-72	-51	-45	-41	-39	-35
Amortization Expense	-3.49	-2.91	-3.06	-3.65	-3.82	-3.46	-3.66	-3.72	-3.97	-2.03	-1.04
Non-Cash Adjustments To Reconcile Net Income	3.56	25	16	6.01	9.14	19	4.59	10	8.43	4.32	14
Changes in Operating Assets and Liabilities, net	-10	13	10	-5.63	-17	15	5.49	2.86	-2.57	13	-5.93
Net Cash From Investing Activities	94	-269	87	62	-99	-16	40	74	20	-138	-6.79
Net Cash From Continuing Investing Activities	94	-269	87	62	-99	-16	40	74	20	-138	-6.79
Purchase of Investments	-11	-376	-13	-	-167	-129	-83	-81	-62	-251	-80
Sale and/or Maturity of Investments	105	107	100	62	68	113	123	155	82	113	73
Net Cash From Financing Activities	0.93	347	3.10	0.68	2.17	258	1.85	1.32	2.47	164	-14
Net Cash From Continuing Financing Activities	0.93	347	3.10	0.68	2.17	258	1.85	1.32	2.47	164	-14
Issuance of Common Equity	0.55	0.63	0.54	0.24	0.31	258	0.26	0.18	0.20	162	0.11
Other Financing Activities, net	0.39	347	2.56	0.44	1.86	0.11	1.59	1.15	2.28	1.40	-14

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	725	613	497	450	301	64	84	137	109	90
Total Current Assets	603	581	490	448	299	62	83	133	109	88
Cash & Equivalents	154	295	74	222	115	25	34	35	24	23
Short-Term Investments	419	275	401	218	178	35	47	95	81	63
Accounts Receivable	11	0.00	-	-	-	-	-	-	-	-
Inventories, net	0.37	0.00	-	-	-	-	-	-	-	-
Prepaid Expenses	8.54	3.29	1.92	1.45	5.68	2.56	2.33	3.36	3.03	1.46
Other Current Assets	10	6.89	12	6.89	-	-	-	-	-	-
Plant, Property, & Equipment, net	0.00	0.01	0.02	0.28	0.19	0.28	0.37	0.27	0.26	0.09
Total Noncurrent Assets	122	32	7.43	0.98	1.56	0.91	0.22	3.48	0.24	1.81
Long-Term Investments	120	30	5.47	0.00	-	-	-	3.25	-	-
Other Noncurrent Operating Assets	2.24	2.17	1.96	0.98	1.56	0.91	0.22	0.23	0.24	1.81
Total Liabilities & Shareholders' Equity	725	613	497	450	301	64	84	137	109	90
Total Liabilities	437	59	30	41	48	32	31	33	25	23
Total Current Liabilities	104	58	29	21	19	18	16	16	10	4.85
Short-Term Debt	12	0.00	-	-	2.29	0.00	-	-	-	-
Accounts Payable	12	9.96	4.35	5.67	3.51	6.18	1.44	2.23	2.38	1.45
Accrued Expenses	60	40	24	14	11	10	13	12	6.77	2.18
Other Current Liabilities	20	8.28	0.44	0.55	0.32	0.48	-	-	-	-
Total Noncurrent Liabilities	333	0.59	0.72	21	30	14	15	17	15	18
Long-Term Debt	332	0.00	0.00	20	18	0.00	-	-	-	-
Capital Lease Obligations	0.00	0.01	0.01	0.00	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	1.58	0.58	0.71	0.71	0.10	0.42	0.14	0.31	0.29	2.92
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	288	554	467	408	252	32	53	104	84	-252
Total Preferred & Common Equity	288	554	467	408	252	32	53	104	84	-252
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.23
Total Common Equity	288	554	467	408	252	32	53	104	84	-260
Common Stock	1,509	1,456	1,161	952	821	527	492	471	389	0.00
Retained Earnings	-1,221	-902	-693	-544	-569	-495	-439	-366	-305	-260
Accumulated Other Comprehensive Income / (Loss)	0.16	0.22	-0.81	0.05	-0.00	0.00	-0.03	-0.14	0.06	0.03

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	641	426	477	543	399	431	460	360
Total Current Assets	549	415	446	454	381	409	442	358
Cash & Equivalents	154	133	105	115	95	97	58	71
Short-Term Investments	358	257	320	320	269	302	375	266
Accounts Receivable	19	-	-	-	-	-	-	-
Inventories, net	4.66	-	-	-	-	-	-	-
Prepaid Expenses	8.46	4.91	4.21	4.67	3.75	3.06	1.91	2.27
Other Current Assets	4.12	20	17	15	14	7.22	5.81	17
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.01	0.01	0.01	0.02	0.02
Total Noncurrent Assets	92	11	31	89	18	22	18	2.03
Long-Term Investments	90	10	30	87	16	19	17	-
Other Noncurrent Operating Assets	2.02	0.97	1.37	1.71	2.54	2.76	1.74	2.03
Total Liabilities & Shareholders' Equity	641	426	477	543	399	431	460	360
Total Liabilities	426	59	43	51	40	31	24	22
Total Current Liabilities	95	59	42	51	39	30	24	21
Accounts Payable	10	4.90	12	8.81	6.05	11	8.06	7.12
Accrued Expenses	56	48	27	33	32	18	15	13
Other Current Liabilities	29	6.36	4.10	8.60	1.01	1.46	0.45	0.48
Total Noncurrent Liabilities	331	0.00	0.14	0.33	0.86	1.13	0.60	0.78
Capital Lease Obligations	1.45	0.00	0.00	0.01	0.01	0.02	-	0.01
Other Noncurrent Operating Liabilities	330	0.00	0.13	0.33	0.85	1.12	0.59	0.77
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	215	366	434	492	359	400	436	338
Total Preferred & Common Equity	215	366	434	492	359	400	436	338
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	215	366	434	492	359	400	436	338
Common Stock	1,521	1,493	1,478	1,467	1,190	1,179	1,170	994
Retained Earnings	-1,306	-1,127	-1,043	-975	-830	-779	-734	-654
Accumulated Other Comprehensive Income / (Loss)	0.53	0.37	-0.82	-0.76	-0.46	-0.57	-	-1.61

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	-100.00%	9,109.56%	0.00%	0.00%	-28.04%	72.79%	94.58%	0.00%	0.00%
EBITDA Growth	-44.05%	-57.68%	-674.36%	137.78%	-22.87%	23.67%	-22.47%	-37.18%	-110.30%	-11.22%	0.00%
EBIT Growth	-47.48%	-51.45%	-675.55%	136.88%	-24.34%	24.09%	-21.99%	-36.97%	-100.08%	-16.20%	0.00%
NOPAT Growth	-47.71%	-51.53%	-505.15%	152.44%	-24.13%	24.17%	-22.47%	-41.56%	-113.36%	3.84%	0.00%
Net Income Growth	-52.25%	-40.19%	-699.13%	134.07%	-30.53%	24.22%	-21.64%	-36.72%	-84.39%	-21.64%	0.00%
EPS Growth	-24.83%	-21.14%	-634.78%	124.60%	-1.63%	36.99%	-0.69%	9.94%	99.79%	-235.36%	0.00%
Operating Cash Flow Growth	-71.17%	-20.14%	-558.88%	140.88%	-40.80%	26.15%	-44.67%	-34.74%	-1,347.98%	83.13%	0.00%
Free Cash Flow Firm Growth	-73.98%	-23.27%	-708.16%	129.91%	-43.00%	26.01%	-51.68%	-22.53%	-631.17%	0.00%	0.00%
Invested Capital Growth	-30.82%	-235.44%	-17.14%	43.53%	25.92%	-0.75%	3.59%	-35.92%	-7.54%	0.00%	0.00%
Revenue Q/Q Growth	48.00%	0.00%	-100.00%	933.89%	0.00%	0.00%	-34.89%	72.79%	1.41%	0.00%	0.00%
EBITDA Q/Q Growth	-5.28%	-18.16%	-1,012.46%	130.23%	-7.26%	8.22%	0.22%	-17.08%	-20.43%	0.00%	0.00%
EBIT Q/Q Growth	-5.68%	-18.67%	-988.26%	129.51%	-7.64%	8.18%	0.27%	-16.07%	-21.78%	0.00%	0.00%
NOPAT Q/Q Growth	-5.75%	-18.48%	-660.20%	141.90%	-8.60%	8.18%	0.21%	-15.57%	-17.32%	0.00%	0.00%
Net Income Q/Q Growth	-7.30%	-18.90%	-970.83%	127.18%	-9.62%	7.94%	0.36%	-15.78%	-14.27%	0.00%	0.00%
EPS Q/Q Growth	-1.92%	-15.06%	-24,700.00%	125.41%	0.00%	13.21%	3.31%	-152.17%	96.25%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-6.20%	-12.98%	-1,227.19%	133.40%	-4.25%	4.38%	-3.51%	-5.12%	-21.08%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-5.57%	-11.09%	-325.62%	124.30%	-2.24%	2.27%	-4.59%	-0.77%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-82.52%	-130.89%	-8,571.78%	-13.93%	-14.12%	0.43%	-9.99%	-20.96%	2.49%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	-1,491.14%	0.00%	0.00%	19.37%	-4,722.61%	-3,843.51%	-5,035.14%	-2,958.73%	-3,726.64%	-3,448.01%	0.00%
Operating Margin	-1,434.43%	0.00%	0.00%	18.77%	-4,708.17%	-3,792.95%	-5,001.71%	-2,938.99%	-3,587.38%	-3,271.61%	0.00%
EBIT Margin	-1,434.43%	0.00%	0.00%	18.91%	-4,722.61%	-3,798.15%	-5,003.49%	-2,951.76%	-3,723.61%	-3,621.21%	0.00%
Profit (Net Income) Margin	-1,346.11%	0.00%	0.00%	17.84%	-4,822.54%	-3,694.59%	-4,875.48%	-2,884.35%	-3,645.25%	-3,846.73%	0.00%
Tax Burden Percent	100.08%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	93.77%	90.90%	98.20%	94.34%	102.12%	97.27%	97.44%	97.72%	97.90%	106.23%	101.48%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-75.69%	-40.98%	-34.10%	7.55%	-51.56%	-132.43%	-94.00%	-64.53%	-58.97%	-36.16%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-50.78%	0.00%	0.00%	7.04%	-39.35%	-78.15%	-68.65%	-50.55%	-45.68%	-25.26%	0.00%
Return on Assets (ROA)	-47.66%	0.00%	0.00%	6.64%	-40.18%	-76.02%	-66.90%	-49.39%	-44.71%	-26.83%	0.00%
Return on Common Equity (ROCE)	-75.69%	-40.98%	-34.10%	7.55%	-51.56%	-132.43%	-94.00%	-64.53%	68.61%	140.77%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-110.63%	-37.78%	-31.95%	6.10%	-29.01%	-177.36%	-139.43%	-58.28%	-52.86%	9.56%	0.00%
Net Operating Profit after Tax (NOPAT)	-238	-161	-106	26	-50	-40	-53	-43	-31	-14	-15
NOPAT Margin	-1,004.10%	0.00%	0.00%	18.77%	-3,295.72%	-2,655.06%	-3,501.20%	-2,057.30%	-2,511.16%	-2,290.13%	0.00%
Net Nonoperating Expense Percent (NNEP)	-17.06%	-8.95%	-9.56%	-0.37%	-13.92%	-22.40%	-19.45%	-14.60%	-14.41%	-22.56%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-37.63%	-29.04%	-22.72%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	510.47%	0.00%	0.00%	18.07%	1,483.52%	1,058.80%	1,139.55%	752.42%	1,091.89%	1,848.64%	0.00%
R&D to Revenue	1,020.47%	0.00%	0.00%	63.17%	3,324.65%	2,834.15%	3,962.16%	2,286.58%	2,595.49%	1,522.97%	0.00%
Operating Expenses to Revenue	1,530.94%	0.00%	0.00%	81.23%	4,808.17%	3,892.95%	5,101.71%	3,038.99%	3,687.38%	3,371.61%	0.00%
Earnings before Interest and Taxes (EBIT)	-340	-230	-152	26	-72	-58	-76	-62	-45	-23	-20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-353	-245	-155	27	-72	-58	-76	-62	-45	-22	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.90	2.72	3.28	2.65	3.60	7.54	2.08	2.05	1.55	0.00	0.00
Price to Tangible Book Value (P/TBV)	3.90	2.72	3.28	2.65	3.60	7.54	2.08	2.05	1.55	0.00	0.00
Price to Revenue (P/Rev)	47.51	0.00	0.00	7.74	599.16	157.08	72.85	101.35	106.92	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	43.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	2.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	32.78	0.00	0.00	4.73	419.16	117.60	19.45	38.11	20.46	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	24.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	25.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	25.21	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	22.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	38.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.19	0.00	0.00	0.05	0.08	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	1.15	0.00	0.00	0.05	0.07	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.13	-1.06	-1.03	-1.05	-1.17	-1.66	-1.36	-1.27	-1.27	-1.30	0.00
Leverage Ratio	1.59	1.09	1.08	1.14	1.28	1.74	1.41	1.31	1.32	1.35	0.00
Compound Leverage Factor	1.49	0.99	1.06	1.07	1.31	1.69	1.37	1.28	1.29	1.43	0.00
Debt to Total Capital	54.40%	0.00%	0.00%	4.65%	7.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.92%	0.00%	0.00%	0.00%	0.84%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	52.48%	0.00%	0.00%	4.65%	6.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	10.84%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	478.44%	0.00%
Common Equity to Total Capital	45.60%	100.00%	100.00%	95.35%	92.61%	100.00%	100.00%	100.00%	100.00%	-389.29%	0.00%
Debt to EBITDA	-0.97	0.00	0.00	0.74	-0.28	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.99	2.45	3.10	-15.52	3.81	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.94	0.00	0.00	0.74	-0.25	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.45	0.00	0.00	0.76	-0.40	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.47	3.73	4.53	-16.02	5.46	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.39	0.00	0.00	0.76	-0.36	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.50	13.11	29.02	15.66	8.95	-8.58	-7.19	-0.29	-1.06	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	216.36%	489.29%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.82	10.00	16.85	21.68	15.84	3.39	5.18	8.45	10.47	18.16	0.00
Quick Ratio	5.64	9.82	16.37	21.27	15.53	3.25	5.02	8.23	10.16	17.84	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-223	-128	-104	17	-57	-40	-54	-36	-29	5.49	0.00
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	22,582.17%	0.00%	0.00%	-36,647.59%	-56,394.05%	-13,470.11%	-4,955.10%	-359,825.00%
Free Cash Flow to Firm to Interest Expense	-45.34	-617.58	-33.22	9.02	-24.31	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-55.77	-772.12	-42.61	15.34	-30.23	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-55.77	-772.12	-42.54	15.27	-30.23	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.00	0.00	0.37	0.01	0.02	0.01	0.02	0.01	0.01	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	594.51	6.41	4.64	4.74	8.00	7.01	7.13	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-61	-46	-14	-12	-21	-28	-28	-29	-21	-20	0.00
Invested Capital Turnover	-0.44	0.00	0.00	-8.56	-0.06	-0.05	-0.05	-0.08	-0.06	-0.06	0.00
Increase / (Decrease) in Invested Capital	-14	-33	-2.02	9.09	7.30	-0.21	1.04	-7.67	-1.50	-20	0.00
Enterprise Value (EV)	776	904	1,051	661	636	178	30	80	25	0.00	0.00
Market Capitalization	1,125	1,505	1,533	1,081	909	238	111	214	130	0.00	0.00
Book Value per Share	$3.37	$7.96	$7.76	$8.27	$6.17	$1.16	$2.14	$4.28	$4.62	($3,798.66)	$0.00
Tangible Book Value per Share	$3.37	$7.96	$7.76	$8.27	$6.17	$1.16	$2.14	$4.28	$4.62	($3,798.66)	$0.00
Total Capital	632	554	467	428	272	32	53	104	84	67	0.00
Total Debt	344	0.01	0.01	20	20	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	332	0.01	0.01	20	18	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-349	-601	-481	-420	-273	-60	-81	-133	-105	-87	0.00
Capital Expenditures (CapEx)	0.00	0.00	-0.23	0.13	0.00	0.00	0.19	0.08	0.26	0.05	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-61	-48	-15	-12	-11	-16	-14	-12	-7.34	-3.38	0.00
Debt-free Net Working Capital (DFNWC)	512	523	461	428	282	44	67	118	98	83	0.00
Net Working Capital (NWC)	500	523	461	428	280	44	67	118	98	83	0.00
Net Nonoperating Expense (NNE)	81	48	43	1.29	23	16	21	17	14	9.76	4.90
Net Nonoperating Obligations (NNO)	-349	-601	-481	-420	-273	-60	-81	-133	-105	-87	0.00
Total Depreciation and Amortization (D&A)	-13	-15	-3.38	0.64	0.00	-0.69	-0.48	-0.15	-0.04	1.09	0.10
Debt-free, Cash-free Net Working Capital to Revenue	-258.70%	0.00%	0.00%	-8.83%	-718.72%	-1,049.90%	-907.78%	-589.94%	-601.39%	-539.55%	0.00%
Debt-free Net Working Capital to Revenue	2,160.57%	0.00%	0.00%	306.15%	18,607.58%	2,898.02%	4,432.50%	5,580.83%	8,044.59%	13,263.16%	0.00%
Net Working Capital to Revenue	2,109.41%	0.00%	0.00%	306.15%	18,456.95%	2,898.02%	4,432.50%	5,580.83%	8,044.59%	13,263.16%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.72)	($2.98)	($2.46)	$0.48	$0.00	($1.84)	($2.92)	($2.90)	($3.22)	($1,519.27)	($453.02)
Adjusted Weighted Average Basic Shares Outstanding	85.62M	70.37M	60.76M	52.06M	0.00	30.24M	25.00M	24.70M	18.24M	68.35K	58.18K
Adjusted Diluted Earnings per Share	($3.72)	($2.98)	($2.46)	$0.46	$0.00	($1.84)	($2.92)	($2.90)	($3.22)	($1,519.27)	($453.02)
Adjusted Weighted Average Diluted Shares Outstanding	85.62M	70.37M	60.76M	53.62M	0.00	30.24M	25.00M	24.70M	18.24M	68.35K	58.18K
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($1.84)	($2.92)	($2.90)	($3.22)	($1,519.27)	($453.02)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.02M	84.97M	68.44K	55.01M	0.00	30.49M	25.37M	21.00M	14.62M	68.35K	58.18K
Normalized Net Operating Profit after Tax (NOPAT)	-238	-161	-106	18	-50	-40	-53	-43	-31	-14	-15
Normalized NOPAT Margin	-1,004.10%	0.00%	0.00%	13.14%	-3,295.72%	-2,655.06%	-3,501.20%	-2,057.30%	-2,511.16%	-2,290.13%	0.00%
Pre Tax Income Margin	-1,345.06%	0.00%	0.00%	17.84%	-4,822.54%	-3,694.59%	-4,875.48%	-2,884.35%	-3,645.25%	-3,846.73%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-68.91	-1,107.28	-48.48	13.91	-30.40	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-48.24	-773.88	-33.86	13.81	-21.21	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-68.91	-1,107.28	-48.41	13.85	-30.40	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-48.24	-773.88	-33.79	13.74	-21.21	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%
EBITDA Growth	-4.85%	-21.93%	-54.13%	-45.74%	-66.42%	-84.80%	-64.76%	-40.71%	-35.84%	-145.58%	-81.66%
EBIT Growth	-5.50%	-23.61%	-58.71%	-49.29%	-72.44%	-85.47%	-59.22%	-31.83%	-25.24%	-143.49%	-76.54%
NOPAT Growth	-5.34%	-23.69%	-58.95%	-49.39%	-72.80%	-85.34%	-60.37%	-31.69%	-24.84%	-130.73%	-75.42%
Net Income Growth	-17.19%	-29.94%	-64.48%	-52.56%	-76.04%	-84.91%	-44.47%	-18.75%	-10.65%	-140.74%	-71.53%
EPS Growth	-15.29%	-6.86%	-34.25%	-25.00%	-44.07%	-61.90%	-25.86%	-3.23%	6.35%	-134.24%	-45.00%
Operating Cash Flow Growth	-13.90%	-38.79%	-39.57%	-102.55%	-112.98%	-80.61%	-56.44%	12.24%	6.45%	-122.73%	-14.43%
Free Cash Flow Firm Growth	835.13%	-141.47%	-157.83%	-271.76%	-93.85%	19.64%	45.25%	71.95%	53.95%	-131.62%	-59.83%
Invested Capital Growth	-1,181.22%	-30.82%	-65.50%	-11.21%	-103.02%	-235.44%	-12,407.98%	-683.64%	-329.83%	-17.14%	101.58%
Revenue Q/Q Growth	160.96%	-38.56%	257.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	11.90%	-7.21%	-18.80%	6.56%	-2.46%	-35.52%	-12.33%	-6.70%	-13.77%	-20.83%	4.07%
EBIT Q/Q Growth	12.85%	-7.62%	-20.51%	6.66%	-2.10%	-38.18%	-13.36%	-7.82%	-9.82%	-18.62%	6.14%
NOPAT Q/Q Growth	13.08%	-7.58%	-20.70%	6.66%	-2.06%	-38.24%	-13.44%	-7.96%	-9.47%	-19.62%	6.85%
Net Income Q/Q Growth	9.90%	-11.94%	-23.60%	5.99%	0.10%	-41.70%	-14.64%	-8.48%	-4.93%	-10.71%	5.77%
EPS Q/Q Growth	10.09%	-11.22%	-22.50%	5.88%	16.67%	-39.73%	-14.06%	-8.47%	6.35%	-8.62%	6.45%
Operating Cash Flow Q/Q Growth	-65.82%	7.92%	13.01%	14.25%	-102.06%	7.40%	-26.24%	9.83%	-71.35%	19.79%	29.18%
Free Cash Flow Firm Q/Q Growth	658.31%	-7.29%	0.69%	-23.57%	-83.39%	-14.56%	-43.20%	35.57%	23.97%	21.95%	26.64%
Invested Capital Q/Q Growth	-536.35%	-82.52%	-63.79%	32.65%	35.02%	-130.89%	-10.07%	-22.95%	-7.36%	-8,571.78%	-94.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.58%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-436.41%	-1,292.64%	-740.82%	-2,227.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-417.91%	-1,254.75%	-716.62%	-2,120.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-419.01%	-1,254.75%	-716.36%	-2,122.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-423.34%	-1,226.16%	-673.01%	-1,944.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.26%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.30%	100.00%
Interest Burden Percent	101.03%	97.46%	93.95%	91.60%	90.95%	92.96%	90.65%	89.64%	89.09%	92.97%	99.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-93.70%	-75.69%	-81.88%	-63.30%	-51.89%	-40.98%	-50.50%	-42.08%	-37.85%	-34.10%	-5.19%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-15,020.86%
Operating Return on Assets (OROA)	-30.95%	-44.42%	-27.78%	-16.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-31.27%	-43.41%	-26.10%	-14.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-93.70%	-75.69%	-81.88%	-63.30%	-51.91%	-40.98%	-50.50%	-42.08%	-37.86%	-34.10%	-5.19%
Return on Equity Simple (ROE_SIMPLE)	-154.01%	0.00%	-81.07%	-60.80%	-48.92%	0.00%	-49.02%	-40.08%	-35.20%	0.00%	-4.12%
Net Operating Profit after Tax (NOPAT)	-59	-67	-63	-52	-56	-55	-39	-35	-32	-29	-25
NOPAT Margin	-292.54%	-878.33%	-501.63%	-1,484.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.67%	-5.63%	-5.50%	-3.69%	-3.44%	-3.32%	-3.26%	-2.53%	-2.15%	-2.17%	-3.95%
Return On Investment Capital (ROIC_SIMPLE)	-27.08%	-10.68%	-	-	-	-9.84%	-	-	-	-6.29%	-
Cost of Revenue to Revenue	4.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	204.73%	490.76%	248.85%	830.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	307.53%	853.24%	567.77%	1,390.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	513.49%	1,344.00%	816.62%	2,220.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-84	-96	-90	-74	-80	-78	-56	-50	-46	-42	-35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-87	-99	-93	-78	-83	-81	-60	-53	-50	-44	-36
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.91	3.90	4.47	4.02	3.37	2.72	2.81	3.60	0.00	3.28	4.02
Price to Tangible Book Value (P/TBV)	4.91	3.90	4.47	4.02	3.37	2.72	2.81	3.60	0.00	3.28	4.02
Price to Revenue (P/Rev)	24.17	47.51	102.38	498.51	0.00	0.00	0.00	0.00	0.00	0.00	10.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	98.75
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.01%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6,265.78
Enterprise Value to Revenue (EV/Rev)	10.43	32.78	77.40	368.62	0.00	0.00	0.00	0.00	0.00	0.00	8.07
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	3.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	1.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.01	1.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.59	-1.13	-1.07	-1.05	-1.05	-1.06	-1.03	-1.02	-1.02	-1.03	-1.02
Leverage Ratio	1.67	1.59	1.14	1.09	1.08	1.09	1.09	1.10	1.09	1.08	1.12
Compound Leverage Factor	1.69	1.55	1.07	1.00	0.98	1.01	0.99	0.99	0.97	1.01	1.11
Debt to Total Capital	0.67%	54.40%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	1.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.67%	52.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.33%	45.60%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.08%	100.00%	100.00%
Debt to EBITDA	0.00	-0.97	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.68	0.99	1.19	1.50	1.87	2.45	1.83	2.28	0.00	3.10	24.18
Long-Term Debt to EBITDA	0.00	-0.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.01	-1.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.50	1.47	1.78	2.26	2.83	3.73	2.79	3.46	0.00	4.53	24.18
Long-Term Debt to NOPAT	-0.01	-1.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.88	-0.39	13.19	22.02	17.34	13.93	12.77	25.76	-1.44	29.75	36.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	-0.04%	0.00%	0.00%	0.00%	-0.04%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.80	5.82	6.99	10.50	8.93	10.00	9.73	13.56	18.61	16.85	17.19
Quick Ratio	5.62	5.64	6.56	10.01	8.55	9.82	9.28	13.22	18.23	16.37	16.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	297	-53	-50	-50	-40	-22	-19	-13	-21	-27	-35
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	36.88	-11.06	-2,154.95	-1,109.05	-734.31	-349.56	-274.62	-383.56	-520.86	-637.27	-20.09
Operating Cash Flow to Interest Expense	-11.82	-11.94	-2,709.65	-1,592.11	-1,519.05	-656.33	-637.90	-1,010.60	-980.70	-532.42	-16.33
Operating Cash Flow Less CapEx to Interest Expense	-11.82	-11.94	-2,709.65	-1,592.11	-1,519.05	-656.33	-637.90	-1,010.60	-980.70	-532.42	-16.20
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.07	0.04	0.04	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.42
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	466.67	0.00	0.00	0.00	0.00	0.00	0.00	1,398.63
Accounts Payable Turnover	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	3,888.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-3,888.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-386	-61	-33	-20	-30	-46	-20	-18	-15	-14	0.16
Invested Capital Turnover	-0.21	-0.44	-0.60	-0.18	0.00	0.00	0.00	0.00	0.00	0.00	-24.86
Increase / (Decrease) in Invested Capital	-356	-14	-13	-2.04	-15	-33	-20	-21	-11	-2.02	11
Enterprise Value (EV)	456	776	1,238	1,290	1,135	904	630	1,022	-448	1,051	1,021
Market Capitalization	1,057	1,125	1,638	1,745	1,657	1,505	1,009	1,440	1.45	1,533	1,359
Book Value per Share	$2.50	$3.37	$4.31	$5.11	$5.77	$7.96	$5.17	$5.81	$6,368.03	$7.76	$5.98
Tangible Book Value per Share	$2.50	$3.37	$4.31	$5.11	$5.77	$7.96	$5.17	$5.81	$6,368.03	$7.76	$5.98
Total Capital	217	632	366	434	492	554	359	400	436	467	338
Total Debt	1.45	344	0.00	0.00	0.01	0.01	0.01	0.02	0.00	0.01	0.01
Total Long-Term Debt	1.45	332	0.00	0.00	0.01	0.01	0.01	0.02	0.00	0.01	0.01
Net Debt	-601	-349	-400	-455	-522	-601	-379	-418	-449	-481	-338
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-58	-61	-34	-22	-31	-48	-22	-20	-15	-15	-1.13
Debt-free Net Working Capital (DFNWC)	454	512	355	404	403	523	342	379	418	461	337
Net Working Capital (NWC)	454	500	355	404	403	523	342	379	418	461	337
Net Nonoperating Expense (NNE)	26	27	21	16	17	18	12	9.84	8.92	9.77	11
Net Nonoperating Obligations (NNO)	-601	-349	-400	-455	-522	-601	-379	-418	-450	-481	-338
Total Depreciation and Amortization (D&A)	-3.49	-2.91	-3.06	-3.65	-3.82	-3.46	-3.66	-3.72	-3.96	-2.03	-1.03
Debt-free, Cash-free Net Working Capital to Revenue	-132.65%	-258.70%	-213.59%	-614.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.89%
Debt-free Net Working Capital to Revenue	1,038.84%	2,160.57%	2,221.45%	11,530.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	266.11%
Net Working Capital to Revenue	1,038.84%	2,109.41%	2,221.45%	11,530.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	266.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.98)	($1.09)	($0.98)	($0.80)	($0.85)	($1.02)	($0.73)	($0.64)	($0.59)	($0.63)	($0.58)
Adjusted Weighted Average Basic Shares Outstanding	86.17M	85.62M	85.43M	85.27M	85.21M	70.37M	69.86M	69.64M	69.44M	60.76M	60.67M
Adjusted Diluted Earnings per Share	($0.98)	($1.09)	($0.98)	($0.80)	($0.85)	($1.02)	($0.73)	($0.64)	($0.59)	($0.63)	($0.58)
Adjusted Weighted Average Diluted Shares Outstanding	86.17M	85.62M	85.43M	85.27M	85.21M	70.37M	69.86M	69.64M	69.44M	60.76M	60.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	86.05M	86.02M	0.00	85.10M	84.99M	84.97M	69.64M	69.48M	68.82M	68.44K	60.22M
Normalized Net Operating Profit after Tax (NOPAT)	-58	-67	-63	-52	-56	-55	-39	-35	-32	-29	-25
Normalized NOPAT Margin	-291.67%	-878.33%	-501.63%	-1,484.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-423.34%	-1,222.94%	-673.01%	-1,944.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.43	-20.05	-3,893.26	-1,651.16	-1,447.29	-1,237.48	-806.01	-1,422.03	-1,154.05	-977.53	-20.27
NOPAT to Interest Expense	-7.28	-14.04	-2,726.26	-1,154.47	-1,012.00	-865.62	-563.55	-993.56	-805.26	-684.27	-14.07
EBIT Less CapEx to Interest Expense	-10.43	-20.05	-3,893.26	-1,651.16	-1,447.29	-1,237.48	-806.01	-1,422.03	-1,154.05	-977.53	-20.14
NOPAT Less CapEx to Interest Expense	-7.28	-14.04	-2,726.26	-1,154.47	-1,012.00	-865.62	-563.55	-993.56	-805.26	-684.27	-13.94
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

When does Syndax Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Syndax Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Syndax Pharmaceuticals' net income changed over the last 10 years?

Syndax Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$318.76 million in 2024, rising from -$19.83 million in 2014. The previous period was -$209.36 million in 2023. See Syndax Pharmaceuticals' forecast for analyst expectations on what’s next for the company.

What is Syndax Pharmaceuticals's operating income?

Syndax Pharmaceuticals's total operating income in 2024 was -$339.67 million, based on the following breakdown:

Total Gross Profit: $23.68 million
Total Operating Expenses: $362.53 million

How has Syndax Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' total revenue changed from $0.00 in 2014 to $23.68 million in 2024, a change of 2,368,000,000.0%.

How much debt does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals' total liabilities were at $436.69 million at the end of 2024, a 644.1% increase from 2023, and a 1,781.9% increase since 2015.

How much cash does Syndax Pharmaceuticals have?

In the past 9 years, Syndax Pharmaceuticals' cash and equivalents has ranged from $23.18 million in 2015 to $295.39 million in 2023, and is currently $154.08 million as of their latest financial filing in 2024.

How has Syndax Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' book value per share changed from 0.00 in 2014 to 3.37 in 2024, a change of 336.5%.

Related Companies

This page (NASDAQ:SNDX) was last updated on 5/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Financials

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Financials

Annual Income Statements for Syndax Pharmaceuticals

Quarterly Income Statements for Syndax Pharmaceuticals

Annual Cash Flow Statements for Syndax Pharmaceuticals

Quarterly Cash Flow Statements for Syndax Pharmaceuticals

Annual Balance Sheets for Syndax Pharmaceuticals

Quarterly Balance Sheets for Syndax Pharmaceuticals

Annual Metrics And Ratios for Syndax Pharmaceuticals

Quarterly Metrics And Ratios for Syndax Pharmaceuticals

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools